The issue in brief

Uniphar's (LSE:UPR) only regulatory filing in the past week was a holdings notice on 11 November 2026, in which Threadneedle Asset Management Holdings disclosed an interest in 9.84 million shares, or 3.79% of the issued capital, as of 9 September. With no fresh trading news, this piece returns to a detail in the Dublin-based group's interim results of 8 September 2026 that bears directly on its Irish business: the revised start date for a new high-technology distribution Facility in Ireland.

The company (LSE:UPR) said the facility would go live in February 2027, with a phased roll-out during the first half of that year. It explained that the extended timeline allowed more end-to-end testing and avoided switching systems during the Supply Chain division's peak fourth-quarter trading season.

Why the Warehouse matters

Supply Chain & Retail is Uniphar's (LSE:UPR) largest division by revenue. In the six months to 30 June 2026 it generated Revenue of €1,069.3m, up 6.9%, Gross Profit of €105.3m, up 7.3%, and EBITDA of €22.9m, up only 2.4%. Its EBITDA Margin slipped to 2.1% from 2.2%. The company attributed the slower profit growth to Investment in its service offer together with Inflation and statutory wage increases.

Management also acknowledged capacity constraints within the current infrastructure, while saying the division continued to grow regardless. It said the new site's build and fit-out were complete and that inspections by the Health Products Regulatory Authority had been carried out. Once fully operating, the company expects the facility to more than double current capacity in the division and to help scale its Pharma platform. It described the investment as a key component of its 2028 profit ambition.

Alongside the Irish project, the company said final phases of new facilities in the Netherlands and the UK would complete during 2026, supporting its Pharma division's growth in continental Europe. Rolling 12-month return on capital employed was 14.7%, down from 15.5% a year earlier but still near the top end of the group's 12% to 15% medium-term target range.

How the rest of the group performed

Group revenue rose 7.2% to €1,591.9m and gross profit 7.7% to €236.5m, of which 6.9% was organic. MedTech was the leading profit performer, with EBITDA up 11.5% to €24.1m on a 15.9% margin. Pharma EBITDA rose 3.9% to €14.0m as the division invested in specialist capabilities. Adjusted Earnings Per Share increased 11.2% to 10.9 cent, and an Interim Dividend of €0.0074 was declared. All figures are reported in euro.

Supply Chain & Retail produced about 67% of group revenue but roughly 38% of divisional EBITDA in the half, which explains why efficiency gains from new infrastructure could matter disproportionately to its returns.

Factors to watch

Warehouse and systems migrations in pharmaceutical wholesale carry real service risk, because pharmacies and hospitals depend on reliable daily deliveries. The company's own decision to add testing time suggests it regards that risk as significant. Until the site is live, capacity limits may continue to constrain the division's growth and margin. The TouchStore acquisition, completed in December 2025 and contributing 1.7 percentage points of the division's gross profit growth, was still being reviewed by Ireland's Competition and Consumer Protection Commission at the time of the interims. Retail also saw some softness in discretionary spending.

Guidance and what comes next

For the full year 2026, the company said Supply Chain & Retail was confident of mid-single-digit organic gross profit growth, against a medium-term target of low single digits. It said group EBITDA growth was set to accelerate in the second half and that it was well positioned to meet adjusted EPS expectations. The next scheduled milestones are full-year results for 2026, for which no date has yet been announced, and the February 2027 go-live itself.